View Video: Our Director of Patient Advocacy moderated an insightful panel discussion at the White House Cancer Moonshot Brain Cancers Forum on GBM & DIPG on May 25, 2023
May 25, 2023
April Freeman Brings Her Personal and Professional Experience to SonALAsense as Patient Advocate
July 28, 2022
April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.
SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer
June 28, 2022
Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.
SonALAsense Q&A with Dr. Scott Plotkin
June 21, 2022
Dr. Scott Plotkin, MD, PhD is the Executive Director at the Pappas Center for Neuro-Oncology at Massachusetts General Hospital and the Giovanni Armenise– Harvard Professor of Neurology at Harvard Medical School. He completed his neurology training at Mass General Brigham and Women's Hospital in Boston in 2002, and then trained in neuro-oncology at Mass General Hospital the following year. He has been on the faculty ever since and now also sits on the Scientific Advisory Board for SonALAsense.
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
September 20, 2021
Trial provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors and other lethal cancers
Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
March 30, 2021
Study combines metabolic targeting of glioblastoma with inert drug activated using MR-guided focused ultrasound